New Report Suggests New Biomarkers For Early Mesothelioma Diagnosis

Because of the extremely long latency period of mesothelioma, diagnosis typically occurs in the advance stages of the cancer which limits the availability of both treatment options and treatment effectiveness. Early diagnosis typically leads to longer survival times however current medical technology has not allowed for a reliable method of predicting which of those exposed to asbestos will develop mesothelioma.

A new study published in PlosOne reports that researchers have found two biomarkers associated with early malignant mesothelioma diagnosis. The markers are types of miRNAs, or the genetic material responsible for the expression of our genes. Researchers found that there are two miRNAs which are found in lesser amounts in patients with malignant mesothelioma. The markers miR-103a-3p and mi-R-30e-3p may be fundamental in catching malignant mesothelioma early enough to provide life extending treatment options

The Paul Law Firm advocates for victims of asbestos-related diseases. If you or a loved one is suffering from mesothelioma, call the Paul Law Firm. With over 2.5 billion dollars collected for victims of asbestos exposure, we have the knowledge and the experience to fight for you. We also understand that fighting doesn’t just happen in the courtroom. It also happens in a lab where we are fighting for a cure. Check out the Mesothelioma Research Foundation of America here.

Call us today at 1-855 88 LEGAL (885-3425) or contact us online to discuss your case with one of our experienced mesothelioma lawyers